25 XP   0   0   10

Pliant Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Pliant Therapeutics Inc together

PenkeI guess you are interested in Pliant Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pliant Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pliant Therapeutics Inc

I send you an email if I find something interesting about Pliant Therapeutics Inc.

Quick analysis of Pliant Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Pliant Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.86
Expected worth in 1 year
$10.52
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$2.66
Return On Investment
18.3%

For what price can you sell your share?

Current Price per Share
$14.55
Expected price per share
$12.61 - $18.00
How sure are you?
50%

1. Valuation of Pliant Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$14.55

Intrinsic Value Per Share

$-18.37 - $-21.43

Total Value Per Share

$-10.51 - $-13.57

2. Growth of Pliant Therapeutics Inc (5 min.)




Is Pliant Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$473.5m$242.9m$274.9m53.1%

How much money is Pliant Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$37.9m-$29.9m-$8m-21.2%
Net Profit Margin-4,893.0%-1,616.9%--

How much money comes from the company's main activities?

3. Financial Health of Pliant Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#119 / 1031

Most Revenue
#459 / 1031

Most Profit
#884 / 1031

Most Efficient
#917 / 1031

What can you expect buying and holding a share of Pliant Therapeutics Inc? (5 min.)

Welcome investor! Pliant Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Pliant Therapeutics Inc.

What can you expect buying and holding a share of Pliant Therapeutics Inc?

First you should know what it really means to hold a share of Pliant Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Pliant Therapeutics Inc is $14.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pliant Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pliant Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.86. Based on the TTM, the Book Value Change Per Share is $0.66 per quarter. Based on the YOY, the Book Value Change Per Share is $0.47 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pliant Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.68-4.7%-0.67-4.6%-0.51-3.5%-0.40-2.7%-0.40-2.7%
Usd Book Value Change Per Share-0.49-3.4%0.664.6%0.473.3%0.392.7%0.392.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.49-3.4%0.664.6%0.473.3%0.392.7%0.392.7%
Usd Price Per Share18.11-20.04-13.81-15.60-15.60-
Price to Earnings Ratio-6.63--7.56--6.60--9.34--9.34-
Price-to-Total Gains Ratio-37.02--25.80--19.46--41.88--41.88-
Price to Book Ratio2.30-2.32-3.29-3.14-3.14-
Price-to-Total Gains Ratio-37.02--25.80--19.46--41.88--41.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.55
Number of shares68
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.660.39
Usd Total Gains Per Share0.660.39
Gains per Quarter (68 shares)45.2226.73
Gains per Year (68 shares)180.88106.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10181171010797
203623520214204
305435330321311
407247140428418
509048950535525
60108510760642632
70126612570748739
80144714380855846
90162816190962953
10018091800010691060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.019.00.05.0%1.019.00.05.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.013.02.025.0%5.013.02.025.0%5.013.02.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.013.02.025.0%5.013.02.025.0%5.013.02.025.0%

Fundamentals of Pliant Therapeutics Inc

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-03-22 00:42:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pliant Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pliant Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -849.4% means that $-8.49 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pliant Therapeutics Inc:

  • The MRQ is -849.4%. The company is making a huge loss. -2
  • The TTM is -4,893.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-849.4%TTM-4,893.0%+4,043.6%
TTM-4,893.0%YOY-1,616.9%-3,276.1%
TTM-4,893.0%5Y-1,620.2%-3,272.8%
5Y-1,620.2%10Y-1,620.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-849.4%-171.8%-677.6%
TTM-4,893.0%-205.8%-4,687.2%
YOY-1,616.9%-262.1%-1,354.8%
5Y-1,620.2%-455.6%-1,164.6%
10Y-1,620.2%-589.0%-1,031.2%
1.1.2. Return on Assets

Shows how efficient Pliant Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • -8.0% Return on Assets means that Pliant Therapeutics Inc generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pliant Therapeutics Inc:

  • The MRQ is -8.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.0%TTM-6.9%-1.1%
TTM-6.9%YOY-11.8%+4.9%
TTM-6.9%5Y-8.3%+1.4%
5Y-8.3%10Y-8.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.0%-12.5%+4.5%
TTM-6.9%-12.2%+5.3%
YOY-11.8%-11.2%-0.6%
5Y-8.3%-13.4%+5.1%
10Y-8.3%-14.7%+6.4%
1.1.3. Return on Equity

Shows how efficient Pliant Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • -8.7% Return on Equity means Pliant Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pliant Therapeutics Inc:

  • The MRQ is -8.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-7.4%-1.3%
TTM-7.4%YOY-13.8%+6.4%
TTM-7.4%5Y-11.5%+4.1%
5Y-11.5%10Y-11.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-15.8%+7.1%
TTM-7.4%-15.7%+8.3%
YOY-13.8%-13.9%+0.1%
5Y-11.5%-18.3%+6.8%
10Y-11.5%-19.2%+7.7%

1.2. Operating Efficiency of Pliant Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pliant Therapeutics Inc is operating .

  • Measures how much profit Pliant Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -971.8% means the company generated $-9.72  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pliant Therapeutics Inc:

  • The MRQ is -971.8%. The company is operating very inefficient. -2
  • The TTM is -5,153.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-971.8%TTM-5,153.3%+4,181.5%
TTM-5,153.3%YOY-1,728.0%-3,425.3%
TTM-5,153.3%5Y-1,697.1%-3,456.2%
5Y-1,697.1%10Y-1,697.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-971.8%-299.1%-672.7%
TTM-5,153.3%-210.1%-4,943.2%
YOY-1,728.0%-279.7%-1,448.3%
5Y-1,697.1%-459.9%-1,237.2%
10Y-1,697.1%-596.9%-1,100.2%
1.2.2. Operating Ratio

Measures how efficient Pliant Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 9.72 means that the operating costs are $9.72 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pliant Therapeutics Inc:

  • The MRQ is 9.718. The company is inefficient in keeping operating costs low. -1
  • The TTM is 59.852. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ9.718TTM59.852-50.134
TTM59.852YOY18.587+41.265
TTM59.8525Y19.328+40.524
5Y19.32810Y19.3280.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.7182.861+6.857
TTM59.8523.193+56.659
YOY18.5873.615+14.972
5Y19.3285.560+13.768
10Y19.3287.396+11.932

1.3. Liquidity of Pliant Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pliant Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 17.72 means the company has $17.72 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pliant Therapeutics Inc:

  • The MRQ is 17.722. The company is very able to pay all its short-term debts. +2
  • The TTM is 20.449. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ17.722TTM20.449-2.727
TTM20.449YOY11.510+8.939
TTM20.4495Y16.276+4.173
5Y16.27610Y16.2760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.7223.986+13.736
TTM20.4494.440+16.009
YOY11.5105.552+5.958
5Y16.2766.158+10.118
10Y16.2766.492+9.784
1.3.2. Quick Ratio

Measures if Pliant Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 32.54 means the company can pay off $32.54 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pliant Therapeutics Inc:

  • The MRQ is 32.543. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 37.569. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ32.543TTM37.569-5.026
TTM37.569YOY20.926+16.643
TTM37.5695Y27.370+10.199
5Y27.37010Y27.3700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.5433.638+28.905
TTM37.5694.168+33.401
YOY20.9265.515+15.411
5Y27.3706.012+21.358
10Y27.3706.209+21.161

1.4. Solvency of Pliant Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pliant Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pliant Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Pliant Therapeutics Inc assets are financed with 7.5% credit (debt) and the remaining percentage (100% - 7.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pliant Therapeutics Inc:

  • The MRQ is 0.075. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.069. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.075TTM0.069+0.006
TTM0.069YOY0.133-0.063
TTM0.0695Y0.136-0.067
5Y0.13610Y0.1360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0750.335-0.260
TTM0.0690.330-0.261
YOY0.1330.267-0.134
5Y0.1360.367-0.231
10Y0.1360.378-0.242
1.4.2. Debt to Equity Ratio

Measures if Pliant Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.1% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pliant Therapeutics Inc:

  • The MRQ is 0.081. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.075. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.081TTM0.075+0.007
TTM0.075YOY0.155-0.081
TTM0.0755Y0.097-0.023
5Y0.09710Y0.0970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0810.376-0.295
TTM0.0750.398-0.323
YOY0.1550.334-0.179
5Y0.0970.429-0.332
10Y0.0970.476-0.379

2. Market Valuation of Pliant Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pliant Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Pliant Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -6.63 means the investor is paying $-6.63 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pliant Therapeutics Inc:

  • The EOD is -5.330. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.634. Based on the earnings, the company is expensive. -2
  • The TTM is -7.556. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.330MRQ-6.634+1.304
MRQ-6.634TTM-7.556+0.921
TTM-7.556YOY-6.605-0.951
TTM-7.5565Y-9.341+1.785
5Y-9.34110Y-9.3410.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.330-2.643-2.687
MRQ-6.634-2.418-4.216
TTM-7.556-2.742-4.814
YOY-6.605-4.123-2.482
5Y-9.341-6.257-3.084
10Y-9.341-6.478-2.863
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pliant Therapeutics Inc:

  • The EOD is -8.708. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.839. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.487. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.708MRQ-10.839+2.131
MRQ-10.839TTM-10.487-0.351
TTM-10.487YOY-8.887-1.601
TTM-10.4875Y-6.944-3.544
5Y-6.94410Y-6.9440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.708-3.244-5.464
MRQ-10.839-2.939-7.900
TTM-10.487-3.478-7.009
YOY-8.887-5.592-3.295
5Y-6.944-8.473+1.529
10Y-6.944-8.881+1.937
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pliant Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.30 means the investor is paying $2.30 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pliant Therapeutics Inc:

  • The EOD is 1.851. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.304. Based on the equity, the company is underpriced. +1
  • The TTM is 2.320. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.851MRQ2.304-0.453
MRQ2.304TTM2.320-0.016
TTM2.320YOY3.286-0.966
TTM2.3205Y3.143-0.823
5Y3.14310Y3.1430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8512.124-0.273
MRQ2.3042.041+0.263
TTM2.3202.118+0.202
YOY3.2862.915+0.371
5Y3.1433.682-0.539
10Y3.1434.114-0.971
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Pliant Therapeutics Inc.

3.1. Institutions holding Pliant Therapeutics Inc

Institutions are holding 110.735% of the shares of Pliant Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Deep Track Capital, LP9.54533.477657500002500004.5455
2023-12-31BlackRock Inc7.97080.0022480151747891611.0793
2023-12-31FMR Inc6.57950.00553963418-177586-4.2885
2023-12-31T. Rowe Price Associates, Inc.6.28480.0092378591643442912.9623
2023-12-31First Light Asset Management, LLC5.96255.2332359177665851622.45
2023-09-30LAURION CAPITAL MANAGEMENT LP5.28980.33713186511279410.8846
2023-12-31Vanguard Group Inc5.08950.001230658691205574.0932
2023-09-30CHI Advisors LLC5.003720.71543014199-102818-3.2986
2023-12-31Blue Owl Capital Holdings LP4.987113.0053300419930041990
2023-09-30Redmile Group, LLC4.44582.2095267809900
2023-09-30TRV GP IV, LLC3.540713.9338213286700
2023-12-31Polar Capital Holdings PLC3.3450.2236201500035000021.021
2023-12-31Great Point Partners LLC3.02665.62751823184680003.8742
2023-12-31Franklin Resources Inc2.62220.01341579572621734.0973
2023-12-31Casdin Capital, LLC2.61812.8036157710800
2023-09-30Citadel Advisors Llc2.52340.00571520078-92829-5.7554
2023-12-31State Street Corporation2.21660.00121335278174771.3262
2023-12-31Pictet Asset Manangement SA2.18930.0263131880441751446.324
2023-12-31RA Capital Management, LLC2.12650.36231281000-481000-27.2985
2023-12-31Geode Capital Management, LLC1.97080.00231187198609845.415
Total 87.33867.995952611593+5096473+9.7%

3.2. Funds holding Pliant Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31T. Rowe Price New Horizons3.16680.1396190763232200320.3076
2023-12-31US Small-Cap Growth II Equity Comp3.16680.1392190763232200320.3076
2024-01-31Polar Capital Biotech S Inc3.07112.0373185000000
2023-12-31Fidelity Growth Compy Commingled Pl O2.87040.04571729098196271.1481
2024-01-31Vanguard Total Stock Mkt Idx Inv2.66640.002160624500
2024-02-01iShares Russell 2000 ETF2.3310.04261404149-9266-0.6556
2023-12-31Fidelity Growth Company Fund2.25770.04591360021-3591-0.2633
2024-01-31DWS ESG Akkumula LC2.15820.2529130008650003562.5004
2023-12-31American Funds SMALLCAP World A1.51470.02391246700
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr1.32870.01498004093510.0439
2024-01-31Franklin Biotechnology Discv A(acc)USD1.10990.68266860000
2023-12-31Fidelity Small Cap Index0.94340.0405568299131002.3595
2023-12-31T. Rowe Price Health Sciences0.89140.0661536985-11162-2.0363
2024-01-31Franklin Small Cap Growth Adv0.86510.34452110000
2023-12-31Franklin US Small Cap Growth Equity0.86510.340452110000
2024-02-28iShares Russell 2000 Growth ETF0.83820.074250495123440.4664
2024-01-31Allspring (Lux) WW Glb L/SEq IPUSD Acc0.83040.41965002499035522.0435
2023-12-31Fidelity Growth Company K60.81460.0534490682-16036-3.1647
2024-01-31Candriam Eqs L Biotech C USD Cap0.7520.494245300000
2024-02-28iShares Biotechnology ETF0.68250.08784111553680.0896
Total 33.12445.345319953860+1230131+6.2%

3.3. Insider Transactions

Insiders are holding 6.63% of the shares of Pliant Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-17Bernard CoulieSELL2572117.23
2024-01-17Hans HullSELL978617.23
2024-01-17Keith Lamont CummingsSELL978117.23
2024-01-17Mike OuimetteSELL519717.23
2023-08-03Hans HullSELL1306920
2023-07-20Mike OuimetteSELL475517.55
2023-07-17Bernard CoulieSELL7015018.01
2023-07-17Eric LefebvreSELL2232118.01
2023-07-17Keith Lamont CummingsSELL1977118.01
2023-07-17Mike OuimetteSELL1277818.01
2023-04-03Mike OuimetteSELL287726.79
2023-03-30Bernard CoulieSELL3533926.52
2023-03-30Eric LefebvreSELL1124526.52
2023-03-30Keith Lamont CummingsSELL996026.52
2023-03-30Mike OuimetteSELL487426.52

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Pliant Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.4890.665-174%0.474-203%0.393-224%0.393-224%
Book Value Per Share--7.8628.597-9%4.034+95%4.303+83%4.303+83%
Current Ratio--17.72220.449-13%11.510+54%16.276+9%16.276+9%
Debt To Asset Ratio--0.0750.069+9%0.133-43%0.136-45%0.136-45%
Debt To Equity Ratio--0.0810.075+9%0.155-48%0.097-16%0.097-16%
Dividend Per Share----0%-0%-0%-0%
Eps---0.682-0.670-2%-0.512-25%-0.396-42%-0.396-42%
Free Cash Flow Per Share---0.418-0.487+17%-0.400-4%-0.277-34%-0.277-34%
Free Cash Flow To Equity Per Share---0.4140.652-164%0.541-176%0.356-216%0.356-216%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.430--------
Intrinsic Value_10Y_min---18.373--------
Intrinsic Value_1Y_max---1.691--------
Intrinsic Value_1Y_min---1.660--------
Intrinsic Value_3Y_max---5.428--------
Intrinsic Value_3Y_min---5.175--------
Intrinsic Value_5Y_max---9.585--------
Intrinsic Value_5Y_min---8.866--------
Market Cap876480360.000-24%1090931912.0001207344166.000-10%831903352.000+31%939942357.200+16%939942357.200+16%
Net Profit Margin---8.494-48.930+476%-16.169+90%-16.202+91%-16.202+91%
Operating Margin---9.718-51.533+430%-17.280+78%-16.971+75%-16.971+75%
Operating Ratio--9.71859.852-84%18.587-48%19.328-50%19.328-50%
Pb Ratio1.851-24%2.3042.320-1%3.286-30%3.143-27%3.143-27%
Pe Ratio-5.330+20%-6.634-7.556+14%-6.6050%-9.341+41%-9.341+41%
Price Per Share14.550-24%18.11020.043-10%13.810+31%15.604+16%15.604+16%
Price To Free Cash Flow Ratio-8.708+20%-10.839-10.487-3%-8.887-18%-6.944-36%-6.944-36%
Price To Total Gains Ratio-29.739+20%-37.016-25.799-30%-19.462-47%-41.880+13%-41.880+13%
Quick Ratio--32.54337.569-13%20.926+56%27.370+19%27.370+19%
Return On Assets---0.080-0.069-14%-0.118+47%-0.083+4%-0.083+4%
Return On Equity---0.087-0.074-15%-0.138+59%-0.115+32%-0.115+32%
Total Gains Per Share---0.4890.665-174%0.474-203%0.393-224%0.393-224%
Usd Book Value--473576000.000517902250.000-9%242979250.000+95%259216300.000+83%259216300.000+83%
Usd Book Value Change Per Share---0.4890.665-174%0.474-203%0.393-224%0.393-224%
Usd Book Value Per Share--7.8628.597-9%4.034+95%4.303+83%4.303+83%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.682-0.670-2%-0.512-25%-0.396-42%-0.396-42%
Usd Free Cash Flow---25163000.000-29320500.000+17%-24097750.000-4%-16679300.000-34%-16679300.000-34%
Usd Free Cash Flow Per Share---0.418-0.487+17%-0.400-4%-0.277-34%-0.277-34%
Usd Free Cash Flow To Equity Per Share---0.4140.652-164%0.541-176%0.356-216%0.356-216%
Usd Market Cap876480360.000-24%1090931912.0001207344166.000-10%831903352.000+31%939942357.200+16%939942357.200+16%
Usd Price Per Share14.550-24%18.11020.043-10%13.810+31%15.604+16%15.604+16%
Usd Profit---41109000.000-37982750.000-8%-29947000.000-27%-20557300.000-50%-20557300.000-50%
Usd Revenue--4839998.0001604999.500+202%2421250.000+100%6127299.900-21%6127299.900-21%
Usd Total Gains Per Share---0.4890.665-174%0.474-203%0.393-224%0.393-224%
 EOD+3 -5MRQTTM+10 -23YOY+19 -145Y+18 -1510Y+18 -15

4.2. Fundamental Score

Let's check the fundamental score of Pliant Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.330
Price to Book Ratio (EOD)Between0-11.851
Net Profit Margin (MRQ)Greater than0-8.494
Operating Margin (MRQ)Greater than0-9.718
Quick Ratio (MRQ)Greater than132.543
Current Ratio (MRQ)Greater than117.722
Debt to Asset Ratio (MRQ)Less than10.075
Debt to Equity Ratio (MRQ)Less than10.081
Return on Equity (MRQ)Greater than0.15-0.087
Return on Assets (MRQ)Greater than0.05-0.080
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Pliant Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.292
Ma 20Greater thanMa 5015.205
Ma 50Greater thanMa 10016.216
Ma 100Greater thanMa 20016.008
OpenGreater thanClose14.330
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,958627-1,331-910-2,241334-1,9072,252345



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets512,154
Total Liabilities38,578
Total Stockholder Equity473,576
 As reported
Total Liabilities 38,578
Total Stockholder Equity+ 473,576
Total Assets = 512,154

Assets

Total Assets512,154
Total Current Assets505,502
Long-term Assets6,652
Total Current Assets
Cash And Cash Equivalents 63,234
Short-term Investments 431,011
Net Receivables 2,997
Other Current Assets 8,260
Total Current Assets  (as reported)505,502
Total Current Assets  (calculated)505,502
+/-0
Long-term Assets
Property Plant Equipment 4,778
Long-term Assets Other 392
Long-term Assets  (as reported)6,652
Long-term Assets  (calculated)5,170
+/- 1,482

Liabilities & Shareholders' Equity

Total Current Liabilities28,524
Long-term Liabilities10,054
Total Stockholder Equity473,576
Total Current Liabilities
Short-term Debt 1,318
Accounts payable 4,531
Other Current Liabilities 22,675
Total Current Liabilities  (as reported)28,524
Total Current Liabilities  (calculated)28,524
+/-0
Long-term Liabilities
Long term Debt 10,054
Long-term Liabilities  (as reported)10,054
Long-term Liabilities  (calculated)10,054
+/-0
Total Stockholder Equity
Common Stock6
Retained Earnings -499,748
Accumulated Other Comprehensive Income 345
Other Stockholders Equity 972,973
Total Stockholder Equity (as reported)473,576
Total Stockholder Equity (calculated)473,576
+/-0
Other
Capital Stock6
Cash and Short Term Investments 494,245
Common Stock Shares Outstanding 59,904
Liabilities and Stockholders Equity 512,154
Net Debt -51,862
Net Invested Capital 483,630
Net Working Capital 476,978
Property Plant and Equipment Gross 13,460
Short Long Term Debt Total 11,372



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-03-31
> Total Assets 
0
55,978
0
0
119,064
184,057
328,803
312,324
295,526
275,254
255,716
234,121
221,215
197,022
184,619
377,181
350,613
597,881
574,891
540,464
512,154
512,154540,464574,891597,881350,613377,181184,619197,022221,215234,121255,716275,254295,526312,324328,803184,057119,0640055,9780
   > Total Current Assets 
0
50,804
0
0
111,900
176,079
324,323
307,729
290,754
270,537
250,719
228,584
209,441
185,363
173,526
365,965
340,311
588,227
565,701
534,335
505,502
505,502534,335565,701588,227340,311365,965173,526185,363209,441228,584250,719270,537290,754307,729324,323176,079111,9000050,8040
       Cash And Cash Equivalents 
0
22,558
0
0
85,807
113,368
178,461
55,224
50,882
50,819
35,193
45,231
51,665
32,545
25,070
44,617
33,685
102,527
54,951
57,679
63,234
63,23457,67954,951102,52733,68544,61725,07032,54551,66545,23135,19350,81950,88255,224178,461113,36885,8070022,5580
       Short-term Investments 
0
0
0
0
16,966
28,063
134,007
238,776
226,012
213,281
208,788
175,813
148,931
145,735
138,527
315,624
297,502
474,787
500,208
465,933
431,011
431,011465,933500,208474,787297,502315,624138,527145,735148,931175,813208,788213,281226,012238,776134,00728,06316,9660000
       Net Receivables 
0
563
0
0
7,385
32,023
3,682
7,214
9,362
2,257
1,913
1,693
2,081
1,332
5,392
2,317
2,066
4,757
4,022
2,122
2,997
2,9972,1224,0224,7572,0662,3175,3921,3322,0811,6931,9132,2579,3627,2143,68232,0237,385005630
       Other Current Assets 
0
0
0
0
1,742
2,625
8,173
6,515
4,498
4,180
4,825
5,847
6,764
5,751
212
207
7,058
418
229
668
8,260
8,2606682294187,0582072125,7516,7645,8474,8254,1804,4986,5158,1732,6251,7420000
   > Long-term Assets 
0
0
0
0
7,164
7,978
4,480
4,595
4,772
4,717
4,997
5,537
11,774
11,659
11,093
11,215
10,302
9,654
9,190
6,129
6,652
6,6526,1299,1909,65410,30211,21511,09311,65911,7745,5374,9974,7174,7724,5954,4807,9787,1640000
       Property Plant Equipment 
0
4,423
0
0
4,079
4,201
4,029
4,144
4,321
4,266
4,367
4,706
10,936
10,824
10,180
10,818
9,908
9,010
8,518
5,737
4,778
4,7785,7378,5189,0109,90810,81810,18010,82410,9364,7064,3674,2664,3214,1444,0294,2014,079004,4230
       Other Assets 
0
751
0
0
3,085
3,777
451
451
451
451
630
831
838
835
913
1
394
0
672
0
0
00672039419138358388316304514514514513,7773,085007510
> Total Liabilities 
0
9,044
0
0
119,499
10,495
12,987
11,978
12,465
11,085
11,736
13,681
22,156
23,229
36,831
40,187
37,271
35,961
41,826
37,416
38,578
38,57837,41641,82635,96137,27140,18736,83123,22922,15613,68111,73611,08512,46511,97812,98710,495119,499009,0440
   > Total Current Liabilities 
0
8,200
0
0
8,172
9,564
12,036
11,026
11,599
10,250
10,932
12,925
16,831
18,309
22,553
26,161
23,913
23,153
29,520
27,395
28,524
28,52427,39529,52023,15323,91326,16122,55318,30916,83112,92510,93210,25011,59911,02612,0369,5648,172008,2000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,869
1,999
2,042
2,649
2,457
2,380
2,232
2,061
1,318
1,3182,0612,2322,3802,4572,6492,0421,9991,869000000000000
       Accounts payable 
0
4,474
0
0
1,250
2,532
2,483
3,140
2,023
2,886
2,764
2,605
2,971
4,684
3,116
3,206
1,580
1,419
2,310
3,360
4,531
4,5313,3602,3101,4191,5803,2063,1164,6842,9712,6052,7642,8862,0233,1402,4832,5321,250004,4740
       Other Current Liabilities 
0
0
0
0
6,922
7,032
9,553
7,886
9,576
7,364
8,168
10,320
10,122
11,626
17,395
20,306
19,876
19,354
24,978
21,974
22,675
22,67521,97424,97819,35419,87620,30617,39511,62610,12210,3208,1687,3649,5767,8869,5537,0326,9220000
   > Long-term Liabilities 
0
0
0
0
111,327
931
951
952
866
835
804
756
5,325
4,920
14,278
14,026
13,358
12,808
12,306
10,021
10,054
10,05410,02112,30612,80813,35814,02614,2784,9205,325756804835866952951931111,3270000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,871
9,900
9,929
9,958
9,988
0
0
009,9889,9589,9299,9009,87100000000000000
       Other Liabilities 
0
844
0
0
0
931
951
952
866
835
804
756
0
0
0
29
0
0
0
0
0
00000290007568048358669529519310008440
       Deferred Long Term Liability 
0
300
0
0
0
3,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000003,4000003000
> Total Stockholder Equity
0
46,934
0
0
-435
173,562
315,816
300,346
283,061
264,169
243,980
220,440
199,059
173,793
147,788
336,994
313,342
561,920
533,065
503,048
473,576
473,576503,048533,065561,920313,342336,994147,788173,793199,059220,440243,980264,169283,061300,346315,816173,562-4350046,9340
   Common Stock
0
1
0
0
1
3
3
3
3
3
3
3
3
3
3
5
5
6
6
6
6
666655333333333310010
   Retained Earnings Total Equity00-417,152-375,960-338,412-303,352-272,737-243,191-215,091-190,560-163,515-140,684-117,82800000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1
59
-30
-18
-32
-18
-30
-40
-201
-950
-1,259
-2,454
-1,958
-1,331
-2,241
-1,907
345
345-1,907-2,241-1,331-1,958-2,454-1,259-950-201-40-30-18-32-18-3059-10000
   Capital Surplus 
0
0
0
0
0
455
0
0
400,918
404,868
407,522
411,037
414,348
417,931
421,781
642,795
653,707
939,205
952,452
0
0
00952,452939,205653,707642,795421,781417,931414,348411,037407,522404,868400,9180045500000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
3
0
0
2,187
241,325
69,307
86,838
400,918
404,868
407,522
411,037
414,348
417,931
421,781
642,795
653,707
939,205
952,452
963,588
972,973
972,973963,588952,452939,205653,707642,795421,781417,931414,348411,037407,522404,868400,91886,83869,307241,3252,1870030



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,580
Cost of Revenue-1,841
Gross Profit-261-261
 
Operating Income (+$)
Gross Profit-261
Operating Expense-183,884
Operating Income-184,145-184,145
 
Operating Expense (+$)
Research Development125,956
Selling General Administrative57,928
Selling And Marketing Expenses0
Operating Expense183,884183,884
 
Net Interest Income (+$)
Interest Income20,484
Interest Expense-1,267
Other Finance Cost-4
Net Interest Income19,221
 
Pretax Income (+$)
Operating Income-184,145
Net Interest Income19,221
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-161,336-206,954
EBIT - interestExpense = -185,412
-161,336
-160,069
Interest Expense1,267
Earnings Before Interest and Taxes (EBIT)-184,145-160,069
Earnings Before Interest and Taxes (EBITDA)-182,304
 
After tax Income (+$)
Income Before Tax-161,336
Tax Provision-0
Net Income From Continuing Ops-155,287-161,336
Net Income-161,336
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses185,725
Total Other Income/Expenses Net22,809-19,221
 

Technical Analysis of Pliant Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pliant Therapeutics Inc. The general trend of Pliant Therapeutics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pliant Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pliant Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 14.36 < 15.18 < 18.00.

The bearish price targets are: 13.43 > 13.40 > 12.61.

Tweet this
Pliant Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pliant Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pliant Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pliant Therapeutics Inc. The current macd is -0.51702764.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pliant Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pliant Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pliant Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Pliant Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartPliant Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pliant Therapeutics Inc. The current adx is 24.73.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pliant Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Pliant Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pliant Therapeutics Inc. The current sar is 17.38.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pliant Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pliant Therapeutics Inc. The current rsi is 42.29. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Pliant Therapeutics Inc Daily Relative Strength Index (RSI) ChartPliant Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pliant Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pliant Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Pliant Therapeutics Inc Daily Stochastic Oscillator ChartPliant Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pliant Therapeutics Inc. The current cci is -90.76202547.

Pliant Therapeutics Inc Daily Commodity Channel Index (CCI) ChartPliant Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pliant Therapeutics Inc. The current cmo is -15.98061266.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pliant Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartPliant Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pliant Therapeutics Inc. The current willr is -74.73684211.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Pliant Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Pliant Therapeutics Inc Daily Williams %R ChartPliant Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pliant Therapeutics Inc.

Pliant Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pliant Therapeutics Inc. The current atr is 0.86005882.

Pliant Therapeutics Inc Daily Average True Range (ATR) ChartPliant Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pliant Therapeutics Inc. The current obv is 67,956,898.

Pliant Therapeutics Inc Daily On-Balance Volume (OBV) ChartPliant Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pliant Therapeutics Inc. The current mfi is 43.83.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pliant Therapeutics Inc Daily Money Flow Index (MFI) ChartPliant Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pliant Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Pliant Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pliant Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.292
Ma 20Greater thanMa 5015.205
Ma 50Greater thanMa 10016.216
Ma 100Greater thanMa 20016.008
OpenGreater thanClose14.330
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pliant Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Pliant Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pliant Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pliant Therapeutics Inc

I send you an email if I find something interesting about Pliant Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Pliant Therapeutics Inc.

Receive notifications about Pliant Therapeutics Inc in your mailbox!